Tesla's Up as Stock-Split Investors Wait, But This Tiny Nasdaq Stock Is Riding High MondayThe Motley Fool • 06/27/22
Axsome Class Action: Levi & Korsinsky Reminds Axsome Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 12, 2022 - AXSMNewsfile Corp • 06/27/22
ROSEN, A TOP RANKED FIRM, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMNewsfile Corp • 06/25/22
AXSM LOSS ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMPRNewsWire • 06/23/22
ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMNewsfile Corp • 06/17/22
AXSM SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AXSMPRNewsWire • 06/14/22
ROSEN, A Leading Law Firm, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMNewsfile Corp • 06/13/22
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the FirmNewsfile Corp • 06/13/22
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMNewsfile Corp • 06/10/22
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the FirmNewsfile Corp • 06/10/22
AXSM SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMPRNewsWire • 06/08/22
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the FirmNewsfile Corp • 06/08/22
Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual MeetingGlobeNewsWire • 06/06/22
AXSM SHAREHOLDER ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSMNewsfile Corp • 06/03/22
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the FirmNewsfile Corp • 06/03/22
Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive DisorderGlobeNewsWire • 06/02/22
Axsome Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 12, 2022 to Discuss Your Rights - AXSMNewsfile Corp • 06/02/22